

**Pterodon pubescens** seed extract induces the cell cycle arrest of leukemic cells by deregulating cyclin D1 and E2 mRNA levels

MONICA FARAH PEREIRA, TATIANA DE ALMEIDA SIMÃO, SÉRGIO RANTO DALMAU, RODOLPHO MATTOS ALBANO, MARSEN GARCIA PINTO COELHO and KATIA COSTA DE CARVALHO SABINO

Departamento de Bioquímica, Instituto de Biologia Roberto Alcantara Gomes, Universidade do Estado do Rio de Janeiro, CEP-20550-170 Rio de Janeiro, RJ, Brazil

Received September 28, 2009; Accepted January 26, 2010

DOI: 10.3892/ol_00000094

Abstract. Plant-derived compounds are important sources of effective anti-cancer agents. *Pterodon pubescens* is a native Brazilian plant popularly known for its anti-inflammatory and anti-arthritic effects. The ethanolic extract of its seeds (EEPp) is a viscous, brown and fragrant oil containing geranylgeraniol, farnesol, naphthalene, dimethyldodecatrienol and vouacapan diterpene derivatives, in addition to other compounds. This study investigated the *in vitro* anti-leukemic properties of EEPp using the resistant human leukemia cell line K562. The EEPp anti-proliferative effect was demonstrated by the inhibition of DNA synthesis and cell growth, and the induction of cell cycle arrest in the G1 phase. Furthermore, cyclin E2 mRNA levels were down-regulated, while those of cyclin D1 were up-regulated. An EEPp anti-leukemic effect may have also triggered apoptosis, as it increased the number of shrunken cells and phosphatidylserine cell membrane exposure. These observations suggest that EEPp deregulates cyclin D1 and E2 expression, inducing cell cycle arrest and apoptosis of leukemic cells.

Introduction

Cancer is the second leading cause of human mortality worldwide, and conventional therapies are known for their serious side effects. Therefore, many efforts have been made to determine novel alternative approaches for the prevention or treatment of cancer. Advances in cancer research have shown that alterations in the expression or function of genes that control the cell cycle and apoptosis enhance tumor survival through the disruption of the balance between these processes. Plants have been used as a source of anti-cancer agents since the 1950s, when the alkaloids vinblastine and vincristine were isolated from *Catharanthus roseus* G. Don. Chemotherapeutic agents in clinical use such as paclitaxel and flavopiridol (1) are also derived from plants. *Pterodon pubescens* Benth. (Leguminosae-Papilionoidea) is popularly known as ‘Sucupira branca’, and its seeds are used in folk medicine to treat rheumatic and inflammatory diseases. Scientific data have confirmed the anti-arthritic effects of the hydroalcoholic extract of *Pterodon pubescens* seeds in type II collagen-induced arthritis in mice without subacute toxic effects (2-4). Although anti-inflammatory action has been noted for the seed ethanolic extract (EEPp) (5), anti-proliferative effects on leukemic cells have yet to be demonstrated. The present study showed that EEPp deregulates cyclin D1 and E2 mRNA expression by inducing cell cycle arrest in the G1 phase and apoptosis in the chronic myelogenous leukemia K562.

Materials and methods

**Extract preparation.** The seeds of *Pterodon pubescens* Benth. were collected by Luciana Pontes Coelho in Goiás, Brazil, and identified by Haroldo Cavalcante de Lima at the Jardim Botânico do Estado do Rio de Janeiro, Brazil, where a voucher was deposited (RB 350279). The powdered seeds were submitted to 100% ethanol (15 g/100 ml) for 15 days. Following ethanol evaporation, the viscous oil (EEPp) was obtained, yielding 50% (w/w). EEPp was dissolved in ethanol and then diluted with a supplemented medium consisting of RPMI-1640 with 10% fetal bovine serum (Cultilab, Brazil), penicillin (70 mg/l) and streptomycin (100 mg/l) to a final ethanol concentration of 0.01%. Control cultures received only 0.01% ethanol in the supplemented medium.

**Cell growth.** The human chronic myelogenous leukemia cell line K562 (CCL-243), purchased from the American Type Culture Collection, was always cultured (2.5x10^5 cells/ml) in the supplemented medium. For cell growth, the cell line was treated with 10, 30 or 50 µg/ml EEPp for 72 h at 37°C and 5% CO₂. Viable cells (by trypan blue dye exclusion) were counted at a 12-h interval.

**Correspondence to:** Dr Katia Costa de Carvalho Sabino, Departamento de Bioquímica, Instituto de Biologia, Centro Biomédico, Universidade do Estado do Rio de Janeiro, Av. Professor Manoel de Abreu 444, 4º Andar, CEP-20550-170 Rio de Janeiro, RJ, Brazil

E-mail: kasabino2000@yahoo.com.br

**Key words:** apoptosis, cell cycle, cyclins, K562 cells, leukemia, *Pterodon pubescens*
Cell proliferation assay. The cells were cultured in 96-well plates (200 µl) with different EEPp concentrations and 0.25 µCi/well [³H]-methyl-thymidine (Amersham Biosciences, Brazil) for 24 h at 37°C in 5% CO₂. Subsequently, the cells were harvested on filter papers and processed for the determination of [³H]-Tdr radioactivity using liquid scintillation.

Cell cycle analysis. Cells were cultured with 30 µg/ml EEPp for 36 h at 37°C in 5% CO₂. After centrifugation (400 x g), 1x10⁶ viable cells were treated with 0.3% Triton X-100 containing 50 µg/ml propidium iodide (PI) in 43 mM citrate buffer solution (pH 8.2) for 15 min in the dark, and then with 500 µl of 100 µg/ml ribonuclease A (Sigma Chemical Co., USA) for 15 min. PI fluorescence (585±15 nm) was measured (100,000 events) using a FACSCalibur cytometer (Beckton-Dickinson, USA), and data were analyzed using the WinMdi 2.8 software.

Analysis of apoptosis using flow cytometry. Cells were treated with 50 µg/ml EEPp for 36 h at 37°C in 5% CO₂. Cell death was evaluated by the loss of membrane integrity (high PI fluorescence at 485 nm) after treatment with PI solution (final concentration 2 µg/ml). Apoptosis was determined by cell shrinkage (size reduction) and evaluated by the forward-scatter (FSC) parameter. Phosphatidylserine exposure was then determined using the Annexin V-FITC/PI double staining kit (BD Pharmingen, USA). Briefly, cells (1x10⁶) were washed with PBS, suspended in binding buffer (10 mM HEPES pH 7.4, 140 mM NaCl and 2.5 mM CaCl₂), and treated with Annexin V (5 µl) and 50 µg/ml PI solution (10 µl) for 15 min at room temperature. Annexin binding was determined by FITC fluorescence (535±15 nm). Cells (10⁵/assay) were obtained using Cell Quest software and analyzed using WinMdi 2.8 software.

Analysis of mRNA expression using RT-PCR. Total RNA was extracted using TRIzol (Invitrogen). The reverse transcription reaction was performed by adding MMLV reverse transcriptase (Invitrogen), RNA and random primers to the reaction mixture. PCR was performed in a Perkin Elmer GeneAmp PCR System 9600. cDNA was added to a 25-µl PCR mixture containing dNTP, the specific primers and Platinum Taq DNA polymerase (Invitrogen). Each cycle consisted of 30 sec at 94°C, 30 sec at annealing temperature, and 1 min at 72°C. The PCR products were resolved on a 2% agarose-ethidium bromide gel and quantified by Lab Image software (Germany). The primers used were: GAPDH (housekeeping gene), forward 5'-TGTGAACGGATTTGGCCGTA-3' and reverse 5'-TCGCTCCTGGAAATGTTGA-3' (58°C, 30 cycles, 200 bp); cyclin D1, forward 5'-CTGCCATAGAAGCTACCTGCA-3' and reverse 5'-ATCCAGGCGTTCGCTGTC-3' (59°C, 30 cycles, 482 bp) and cyclin E2, forward 5'-ATCCAGGCGTTCGCTGTC-3' and reverse 5'-GCACAAGGGCGAGCAGGTC-3' (63°C, 32 cycles, 612 bp).

Statistical analysis. Significant differences between the two groups were assessed using Student's t-test, with a level of significance set at p<0.05.
incorporation of $^3$H-Tdr to DNA was significantly inhibited after a 24-h incubation (Fig. 1A). This effect began at 5 $\mu$g/ml EEPp (p<0.05), reaching 44% inhibition at 30 $\mu$g/ml (p<0.001). EEPp also induced a concentration- and time-dependent cell growth inhibition (Fig. 1B). When cultures were treated with EEPp at 30 $\mu$g/ml, cell growth was only slightly inhibited, while intense and continuous inhibition levels (70-80%) were observed at 50 $\mu$g/ml.

The anti-proliferative effects of EEPp with regard to other cell cycle phases were also studied. The histograms in Fig. 2 show a nuclear PI fluorescence distribution that is proportional to the DNA content (FL2-A). EEPp at 50 $\mu$g/ml effectively arrested K562 cell cycle progression from the G1 to the S phase (Fig. 2, lower panel). Apoptotic bodies, nuclear fragments or nuclear doublets were eliminated from the analysis. In this representative experiment, 50 $\mu$g/ml EEPp induced a 45% increase in cells at the G1 phase, while cell numbers at the S and G2/M phases reciprocally decreased by 16 and 60%, respectively. These effects were confirmed by analyzing the mean of three independent experiments (data not shown).

The relative number of cells at G0/G1, S and G2/M phases in the control cultures was 40.1±1.2, 40.2±1.1 and 18.7±0.9%,
respectively. In the presence of 50 µg/ml EEPp these numbers changed to 60.2±2.5% (50% increase, p<0.01), 31.8±2.6% (21% reduction, p=0.054) and 7.9±0.1% (58% reduction, p<0.01), respectively.

Analysis of cyclin mRNA expression using RT-PCR is shown in Fig. 3A. Control cultures exhibited a reduction in cyclin D1 mRNA levels at 12 h and an increase at 24 h (Fig. 3B), similar to cyclin E2 mRNA levels (Fig. 3C). EEPp at 30 µg/ml induced a higher cyclin D1 mRNA expression at all of the times analyzed (Fig. 3B). This concentration caused a reduction in cyclin E2 expression at 6 h and an increase at 12 h (Fig. 3C).

Apart from inhibiting cell proliferation and inducing cell cycle arrest at the G1 phase, EEPp at 50 µg/ml also induced K562 cell death (Fig. 4A). An increase in the relative number of shrunken cells from 6.4 to 32% (Fig. 4B) indicated that EEPp induces leukemic cells into apoptosis, which was confirmed by the increase in Annexin V-positive cells from 5.7 to 15.4% (Fig. 4C).

Discussion

Many plant products have been found to possess chemotherapeutic activities both in vitro and in vivo (6). This study noted the anti-proliferative activity of EEPp on chronic myelogenous leukemia-derived K562 cells. EEPp inhibited DNA synthesis, cell growth and arrested the cell cycle at the G1 phase, similar to other plant extracts with anti-tumoral activity (6). This effect was not due to ethanol, since ethanol treatment of the control cultures did not alter the responses (data not shown). Vieira and collaborators reported the anti-proliferative activity of a crude ethanolic extract of *Pterodon pubescens* seeds against the human melanoma cell line SK MEL 37, but data were not presented (7).

Cyclins D1 and E2 activate specific cyclin-dependent kinases, inducing the cell cycle progression from the G1 to S phase. In contrast to conventional drugs which inhibit tumor cell line proliferation by reducing cyclin D1 mRNA levels, EEPp treatment increased it. Similar results have been reported for other cell lines (8). The reduction in cyclin E2 mRNA expression in tumor cells by EEPp treatment (6 h) has also been described for several anti-cancer agents (9).

Traditional chemotherapeutic agents and potential anti-cancer drugs (6) deregulate cell cycle components, triggering apoptosis in tumor cells. EEPp induced K562 cells into apoptosis despite their mutated TP53 tumor suppressor gene and resistance to several anti-cancer drugs (10), suggesting that this effect occurs through a p53-independent mechanism.

EEPp is a viscous, brown and fragrant oil, containing geranylgeraniol, farnesol, naphthalene, dimethyldecatrienol and vouacapan diterpene derivatives (5,7). A vouacapan diterpene, isolated from a *Pterodon pubescens* extract, was shown to reduce proliferation and induce apoptosis of melanoma cells (7). The compounds geranylgeraniol and farnesol were shown to induce tumor cell anti-proliferative effects (11) and apoptosis (12,13). Thus, different substances present in EEPp may be involved in its anti-leukemic effects.

This study showed that the ethanolic extract of *Pterodon pubescens* seeds induced the cell cycle arrest and apoptosis of a resistant leukemic cell line and that the deregulation of D1 and E2 cyclin mRNA expression may be related to these anti-proliferative effects. The fractionation of this extract as well as experiments to clarify other mechanisms involved in the anti-leukemic effects of EEPp are currently in progress.

Acknowledgements

We thank the LIA-BPPN Laboratory personnel for their technical assistance. This study was supported by FAPERJ (E-26/171.330/2006).

References